Exchange: NYSEArca·Updated 04:15 PM EDT

TCAF News

News
all
press releases
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.
Stocktwits
BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio
Goldman raised the price target on BioNTech SE to $142, up from $115.
Stocktwits
Why Did BioNTech Stock Surge 10% Pre-Market Today?
DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.
Stocktwits
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.
Stocktwits

Advertisement|Remove ads.